<DOC>
	<DOCNO>NCT01645969</DOCNO>
	<brief_summary>This multicenter , prospective , observational study evaluate one-year outcome HBeAg positive chronic hepatitis B patient receive Pegasys ( peginterferon alfa-2a ) Arm A study ML22265 . Data collect patient one year post-therapy .</brief_summary>
	<brief_title>A Follow-Up Study Patients With HBeAg Positive Chronic Hepatitis B Treated With Pegasys ( Peginterferon Alfa-2a ) Study ML22265</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients randomize study Arm A ML22265 treat complete followup study , regardless treatment response time point Patients unwilling provide inform consent abide requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>